clinical trials

FDA warns about deaths in cancer drug trials
FDA warns about deaths in cancer drug trialsAn increased risk of deaths for patients in clinical trials receiving this cancer drug and two other drugs led FDA to stop the clinical trials.
The Top 7 Craziest Drugs in the Pipeline
The Top 7 Craziest Drugs in the PipelineNot all drugs are incredible—and sometimes even the incredible ones have weird origins.
FDA Warning on KeytrudaAfter trials halted, FDA issues warning on off-label use of the drug.
Pharmacist Intervention Improves Diabetes Drug TrialsInterventions by pharmacists can help improve the results of diabetes clinical trials.
Payers to pharma: Here’s what we’re missing in hep C drugsA Precision for Value survey highlights what can be done in order to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
How precision medicine is improving patient lives: Real examplesAn expert at the Precision Medicine World Conference shared cancer patient perspectives on the importance of immuno-oncology and breakthrough targeted therapies and how they have extended their lives.
HHS makes clinical trials more transparentHHS finalized ClinicalTrial.gov rules encourage healthcare improvement and public benefit by increasing transparency and accountability across the industry.
IRIS Registry may do more than improve patient outcomesThe IRIS Registry can improve patient outcomes by giving physicians access to information that could identify potential areas of quality improvement based on their patient population.
IPF drug to be tested with add-on therapyBoehringer Ingelheim recently began a clinical trial to assess the safety and tolerability of adding on pirfenidone to Ofev (nintedanib) for idiopathic pulmonary fibrosis patients.
New bill aims to speed FDA approval of drugs and medical devicesA new bill looks to decrease the time for the development and release of new drugs and medical devices by modernizing clinical trials and removing barriers to collaboration and innovation, according to legislators.